10-Q: agilon health Appoints Tim O'Rourke as CEO, Reports Q1 2026 Results

agilon health, inc. announced the appointment of Tim O'Rourke as CEO and reported a significant increase in net income and Adjusted EBITDA for the first quarter of 2026, despite a decrease in total revenue.

Summary

• agilon health, inc. has appointed Tim O'Rourke as its new President and Chief Executive Officer, effective May 7, 2026. He will also join the Board of Directors.
• The company reported Q1 2026 results showing a total revenue of $1.42 billion, a decrease of 7% compared to Q1 2025.
• Gross profit increased by 28% to $65 million, and medical margin rose by 16% to $149 million.
• Net income attributable to common shares surged by 304% to $48.9 million, or $2.95 per share (basic), compared to $12.1 million, or $0.73 per share, in Q1 2025.
• Adjusted EBITDA saw a substantial increase of 162% to $53.8 million from $20.6 million in the prior year's quarter.
• Medicare Advantage (MA) members decreased by 13% to 426,300, attributed to market exits and a disciplined contracting approach focused on profitability.
• The company completed a 1-for-25 reverse stock split on March 30, 2026, and has since regained compliance with NYSE minimum share price requirements.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as positive due to significant improvements in profitability metrics and the strategic appointment of a new CEO, despite a decline in revenue and membership.

Positives

• Significant increase in net income, up 304% to $48.9 million.
• Substantial growth in Adjusted EBITDA, up 162% to $53.8 million.
• Improvement in gross profit by 28% to $65 million.
• Medical margin increased by 16% to $149 million.
• Successful appointment of a new CEO, Tim O'Rourke, with a clear commencement date.
• Regained compliance with NYSE minimum share price requirement following a reverse stock split.

Negatives

• Total revenue decreased by 7% to $1.42 billion.
• Medicare Advantage membership declined by 13% due to market and payor exits.
• Ongoing legal proceedings, including consolidated securities and derivative lawsuits, with outcomes uncertain.
• The company's common stock was previously non-compliant with NYSE minimum share price requirements, though compliance has been regained.

Risks

• The company may be unable to comply with continued listing requirements of the NYSE, potentially leading to delisting.
• Ongoing legal proceedings, including securities class action and stockholder derivative lawsuits, could result in material adverse effects.
• Medical expenses incurred on behalf of members may exceed revenues received.
• Failure to identify and develop successful new geographies, physician partners, and payors, or execute growth initiatives.
• Inaccuracy in estimates of members' risk adjustment factors, medical services expense, incurred but not reported claims, and earnings pursuant to payor contracts.
• Public health crises, such as COVID-19, could adversely affect the company.
• The company's stock price may be volatile and subject to factors beyond its control.

Future Outlook

The company's business model is designed to empower primary care physicians to manage health outcomes and total healthcare needs of their Medicare patients. Management believes its model provides the necessary capabilities, capital, and business model for physician groups to create a Medicare-centric, globally capitated line of business. The company expects platform support costs to decrease as a percentage of revenue over time as physician partners add members and revenue grows. Management believes existing cash, cash equivalents, marketable securities, and available borrowing capacity will be sufficient to meet working capital and capital expenditure needs for at least the next 12 months, but may require additional capital resources in the future.

Management Comments

• We believe that PCPs, with their intimate patient-physician relationships, are best positioned to drive meaningful change in quality, cost, and patient experience when provided with the right infrastructure and payment model.
• We believe our purpose-built model provides the necessary capabilities, capital, and business model for existing physician groups to create a Medicare-centric, globally capitated line of business.
• Our model operates by forming risk-bearing entities (RBEs) within local geographies, which enter into arrangements with payors providing for monthly payments to manage the total healthcare needs of our physician partners attributed patients (or, global capitation arrangements).
• The decline in medical services revenue was partially offset by more constructive rates for 2026 from both CMS funding driven by higher premium yield, increased expectations for risk adjustment contribution, more favorable percentage of premium as a result of payor contract negotiations, and a new payor relationship in an existing geography.

Industry Context

StockSavvy.ai notes that agilon health's Q1 2026 results reflect a strategic shift towards profitability, evidenced by the decrease in MA membership and revenue, coupled with significant improvements in profitability metrics like net income and Adjusted EBITDA. The appointment of a new CEO signals a potential new phase for the company, likely focused on sustainable growth and operational efficiency within the evolving Medicare Advantage and value-based care landscape.

Comparison to Industry Standards

• The company's medical margin of $148.9 million represents a 16% increase year-over-year, indicating improved operational efficiency in managing medical costs relative to revenue, a key performance indicator in the value-based care sector.
• The significant increase in Adjusted EBITDA (162%) suggests that agilon health is effectively controlling its operating expenses relative to its revenue generation, a positive trend compared to many healthcare providers facing margin pressures.
• The decrease in MA membership by 13% is a notable strategic decision. While this impacts top-line revenue, it aligns with a broader industry trend of providers becoming more selective in their value-based care contracts to ensure profitability, moving away from pure volume growth.
• The company's focus on Medicare Advantage and CMS ACO Models places it directly within the rapidly growing segment of the healthcare industry focused on senior care and government-sponsored health plans, where efficiency and quality are paramount.

Management Changes

Legal Proceedings

• Three putative securities class action lawsuits consolidated as In re agilon health, inc. Securities Litigation, No. 1:24-cv-00297 (W.D. Tex.), alleging misstatements concerning financial guidance, medical margin, Adjusted EBITDA, growth strategy, and data management.
• Two putative stockholder derivative actions consolidated as In re agilon health, inc. Shareholder Derivative Litigation, No. 1:24-cv-00531 (W.D. Tex.), asserting claims related to alleged misstatements and breach of fiduciary duty.
• A putative securities class action, Vandersluis v. agilon health, Inc., No. 1:25-cv-07167 (E.D.N.Y.), alleging misstatements concerning financial guidance, medical margin, and Adjusted EBITDA.
• A putative stockholder derivative action, Sinha v. Sell et al., No. 1:26-cv-00846 (E.D.N.Y.), asserting claims related to alleged misstatements and breach of fiduciary duty.

Related Party Transactions

• The Company's largest shareholder is an investment fund associated with Clayton Dubilier & Rice, LLC (CD&R), a private equity firm. All funds affiliated with CD&R are considered related parties.
• Loans to physician partners primarily represent loans in connection with taxes payable on shares distributed to them in connection with the Company's initial public offering.

Stakeholder Impact

• Shareholders: Positive impact from improved profitability and regained NYSE compliance, but potential dilution from future capital raises and ongoing legal risks.
• Employees: Potential positive impact from company's improved financial performance, but also potential impact from cost management initiatives.
• Physician Partners: Continued partnership model, with potential for increased incentive payments due to higher margins, but also subject to the company's disciplined contracting approach.
• Payors: Continued engagement with Medicare Advantage payors, with a focus on profitability-driven contracting.

Next Steps

• Tim O'Rourke to commence as CEO and join the Board of Directors on May 7, 2026.
• Continued focus on disciplined contracting and profitability.
• Ongoing management of legal proceedings.
• Monitoring of NYSE listing compliance.

Key Dates

Recommendation

The company shows strong signs of improved profitability and has successfully navigated a critical NYSE listing issue. However, the decrease in revenue and membership, coupled with ongoing significant legal proceedings, warrants a cautious approach. The appointment of a new CEO introduces an element of uncertainty regarding future strategy execution. Therefore, a 'hold' recommendation is appropriate, pending further clarity on the new CEO's strategic direction and the resolution of legal matters.

Keywords

agilon health, Tim O'Rourke, CEO appointment, Q1 2026 earnings, healthcare, Medicare Advantage, capitation, financial results, Adjusted EBITDA, medical margin, NYSE compliance